About AbRegen

Therapeutic antibodies for regenerative medicine.

AbRegen is a development company that specialises in antibody based therapeutics to treat epithelial lesions of skin and other organs.

AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.

AbRegen owns intellectual property related to the modulation of Flightless I, a key regulator of cell growth and migration.  The technology has application to disorders of cellular movement and proliferation, including non-healing chronic wounds, burn injury, cancer and fragile skin disorders.

AbRegen’s current development program is focussed on an antibody-based therapy for epidermolysis bullosa.  A topical anti-flightless I treatment holds significant potential to promote wound repair, decrease skin fragility and inhibit growth of the aggressive squamous cell carcinomas that affect patients with severe forms of this genetic disorder.

AbRegen Board and Management

Professor Allison Cowin

Professor Allison Cowin is a leader in wound healing, internationally renowned for her work on the cytoskeletal protein Flightless I and how it negatively impacts on tissue repair. She is an NHMRC Senior Research Fellow and Professor of Regenerative Medicine at the Future Industries Institute UniSA, leading a group of 10 research scientists and students investigating all aspects of wound healing and regenerative biology. Her research on the cytoskeletal protein Flightless I has resulted in over 130 research articles, editorials and book chapters. She was made a Fellow of Wounds Australia in 2014, was an SA finalist in the Telstra Women’s Business awards in 2015 and was recognised internationally for her Contribution to Clinical and Preclinical research in 2016. She was the founding President of the Australasian Wound & Tissue Repair Society, is the Editor-in -Chief of Wound Practice and Research, Associate Editor for US Journal Wound Repair and Regeneration, and is a Board member of the Australian Society for Dermatology Research. She is the key innovator and inventor of AbRegen’s intellectual property portfolio with patents granted in the USA, Europe, Australia, Canada and Japan.

Dr Prashanth Rajan

Prashanth is the operations manager at AbRegen. Prashanth has a background in technology commercialisation, biomedical research and start-ups. Prashanth is a part of the commercialisation team at UniSA Ventures, working on identifying, protecting and commercialising intellectual property, and manages the IP portfolio. He is experienced in developing business and product development plans, customer discovery and market validation, commercial grant writing and venture capital raising.

Prashanth has a PhD in biochemistry, molecular biology and pharmacology from the Institute for Molecular Bioscience at the University of Queensland. He is well connected into the start-up universe having previously started up a pain-management application at the University of Queensland.

Dr David Belford

Dr David Belford is the Chairman of AbRegen.  Dr Belford has over 20 years experience in scientific research and translational activities.  After pursing a research career within the Commonwealth Scientific and Industrial Research Organisation and Cooperative Research Centre for Tissue Growth and Repair, where he was Leader of the Wound Healing Program, Dr Belford joined the start-up company GroPep Pty Ltd.  He was a member of the senior management team that took GroPep Ltd to its successful IPO, and as Medical Director subsequently established the company’s product development capabilities, consolidating preclinical, analytical, regulatory and clinical activities.  Following the acquisition of GroPep by Novozymes A/S (for ~AUD$100M), he took a role as a Business Development Manager with the Novozymes’ Copenhagen-based Business Development and Acquisitions group before accepting the role as the foundation Director of Research for the Wound Management Innovation Cooperative Research Centre.  Dr Belford holds a first class honours degree in science and a medical degree from the Flinders University of South Australia, and a PhD from the John Curtin School of Medical Research (Australian National University). 

Dr Viraj Perera

Dr Viraj Perera is a non-executive board member.  Dr Perera is the CEO of UniSA Ventures and has extensive expertise in innovation, SME development, technology transfer and commercialisation and Intellectual Property Rights in several countries. He most recently held a position in the Malaysian Government, leading a public-private Technology Commercialisation Platform (PlaTCOM Ventures) which has a focus on university-industry technology transfer, new product development and commercialisation within the SME sector. This role led to Dr Perera being recognised by the International Business Review Magazine as one of the Top 60 Influencers in Malaysia in driving and influencing the Malaysian economy. Prior to this, Dr Perera held senior technology transfer and business development roles at Oxford University and the University of Warwick in the UK, and here in Australia.

Therapeutic antibodies for regenerative medicine.

AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.